• Something wrong with this record ?

Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection

J. Tuma, YJ. Chen, MG. Collins, A. Paul, J. Li, H. Han, R. Sharma, N. Murthy, HY. Lee

. 2023 ; 62 (24) : 3533-3547. [pub] 20230920

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24000212

Grant support
R21 AG072423 NIA NIH HHS - United States
R33 AI119115 NIAID NIH HHS - United States
U19 NS132303 NINDS NIH HHS - United States
R01 MH125979 NIMH NIH HHS - United States
R01 EB029320 NIBIB NIH HHS - United States
UG3 NS115599 NINDS NIH HHS - United States
UM1 AI164559 NIAID NIH HHS - United States
R33 DA048444 NIDA NIH HHS - United States

Neurological disorders are often debilitating conditions with no cure. The majority of current therapies are palliative rather than disease-modifying; therefore, new strategies for treating neurological disorders are greatly needed. mRNA-based therapeutics have great potential for treating such neurological disorders; however, challenges with delivery have limited their clinical potential. Lipid nanoparticles (LNPs) are a promising delivery vector for the brain, given their safer toxicity profile and higher efficacy. Despite this, very little is known about LNP-mediated delivery of mRNA into the brain. Here, we employ MC3-based LNPs and successfully deliver Cre mRNA and Cas9 mRNA/Ai9 sgRNA to the adult Ai9 mouse brain; greater than half of the entire striatum and hippocampus was found to be penetrated along the rostro-caudal axis by direct intracerebral injections of MC3 LNP mRNAs. MC3 LNP Cre mRNA successfully transfected cells in the striatum (∼52% efficiency) and hippocampus (∼49% efficiency). In addition, we demonstrate that MC3 LNP Cas9 mRNA/Ai9 sgRNA edited cells in the striatum (∼7% efficiency) and hippocampus (∼3% efficiency). Further analysis demonstrates that MC3 LNPs mediate mRNA delivery to multiple cell types including neurons, astrocytes, and microglia in the brain. Overall, LNP-based mRNA delivery is effective in brain tissue and shows great promise for treating complex neurological disorders.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000212
003      
CZ-PrNML
005      
20240213093021.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.biochem.3c00371 $2 doi
035    __
$a (PubMed)37729550
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tuma, Jan $u The Department of Cellular and Integrative Physiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States $u Department of Pathophysiology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 75, 323 00 Plzen, Czech Republic $1 https://orcid.org/0000000271978482
245    10
$a Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection / $c J. Tuma, YJ. Chen, MG. Collins, A. Paul, J. Li, H. Han, R. Sharma, N. Murthy, HY. Lee
520    9_
$a Neurological disorders are often debilitating conditions with no cure. The majority of current therapies are palliative rather than disease-modifying; therefore, new strategies for treating neurological disorders are greatly needed. mRNA-based therapeutics have great potential for treating such neurological disorders; however, challenges with delivery have limited their clinical potential. Lipid nanoparticles (LNPs) are a promising delivery vector for the brain, given their safer toxicity profile and higher efficacy. Despite this, very little is known about LNP-mediated delivery of mRNA into the brain. Here, we employ MC3-based LNPs and successfully deliver Cre mRNA and Cas9 mRNA/Ai9 sgRNA to the adult Ai9 mouse brain; greater than half of the entire striatum and hippocampus was found to be penetrated along the rostro-caudal axis by direct intracerebral injections of MC3 LNP mRNAs. MC3 LNP Cre mRNA successfully transfected cells in the striatum (∼52% efficiency) and hippocampus (∼49% efficiency). In addition, we demonstrate that MC3 LNP Cas9 mRNA/Ai9 sgRNA edited cells in the striatum (∼7% efficiency) and hippocampus (∼3% efficiency). Further analysis demonstrates that MC3 LNPs mediate mRNA delivery to multiple cell types including neurons, astrocytes, and microglia in the brain. Overall, LNP-based mRNA delivery is effective in brain tissue and shows great promise for treating complex neurological disorders.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a vodící RNA, systémy CRISPR-Cas $7 D000094704
650    _2
$a mozek $7 D001921
650    _2
$a messenger RNA $x genetika $7 D012333
650    12
$a nemoci nervového systému $7 D009422
650    12
$a nanočástice $7 D053758
650    _2
$a malá interferující RNA $7 D034741
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chen, Yu-Ju $u The Department of Cellular and Integrative Physiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States $1 https://orcid.org/0000000211971086
700    1_
$a Collins, Michael G $u The Department of Cellular and Integrative Physiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States $1 https://orcid.org/0000000231610595
700    1_
$a Paul, Abhik $u The Department of Cellular and Integrative Physiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States $1 https://orcid.org/0000000337972439
700    1_
$a Li, Jie $u Department of Bioengineering, University of California, Berkeley, California 94720, United States $u The Innovative Genomics Institute, 2151 Berkeley Way, Berkeley, California 94704, United States $1 https://orcid.org/0000000301892787
700    1_
$a Han, Hesong $u Department of Bioengineering, University of California, Berkeley, California 94720, United States $u The Innovative Genomics Institute, 2151 Berkeley Way, Berkeley, California 94704, United States $1 https://orcid.org/0000000155455238
700    1_
$a Sharma, Rohit $u Department of Bioengineering, University of California, Berkeley, California 94720, United States $u The Innovative Genomics Institute, 2151 Berkeley Way, Berkeley, California 94704, United States $1 https://orcid.org/0000000314285521
700    1_
$a Murthy, Niren $u Department of Bioengineering, University of California, Berkeley, California 94720, United States $u The Innovative Genomics Institute, 2151 Berkeley Way, Berkeley, California 94704, United States $1 https://orcid.org/0000000278157337
700    1_
$a Lee, Hye Young $u The Department of Cellular and Integrative Physiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States $1 https://orcid.org/0000000231506886
773    0_
$w MED00009310 $t Biochemistry (Easton) $x 1520-4995 $g Roč. 62, č. 24 (2023), s. 3533-3547
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37729550 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093018 $b ABA008
999    __
$a ok $b bmc $g 2049096 $s 1209906
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 62 $c 24 $d 3533-3547 $e 20230920 $i 1520-4995 $m Biochemistry (Easton) $n Biochemistry $x MED00009310
GRA    __
$a R21 AG072423 $p NIA NIH HHS $2 United States
GRA    __
$a R33 AI119115 $p NIAID NIH HHS $2 United States
GRA    __
$a U19 NS132303 $p NINDS NIH HHS $2 United States
GRA    __
$a R01 MH125979 $p NIMH NIH HHS $2 United States
GRA    __
$a R01 EB029320 $p NIBIB NIH HHS $2 United States
GRA    __
$a UG3 NS115599 $p NINDS NIH HHS $2 United States
GRA    __
$a UM1 AI164559 $p NIAID NIH HHS $2 United States
GRA    __
$a R33 DA048444 $p NIDA NIH HHS $2 United States
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options